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Background
Non AIDS-defining cancers (NADC) have emerged as a
growing problem in the HIV-positive population, espe-
cially given that HIV-infected patients are living longer
with antiretroviral therapy (ART). HIV-Tat protein appears
to have oncogenic properties in colorectal cancer cells in
vitro. To date, there has been no large series studying HIV-
associated colon adenocarcinoma. Therefore, the aim of
this study was to examine the clinicopathologic features
of this NADC in a series of HIV-positive patients.
Methods
Cases of HIV-associated colon adenocarcinoma (exclud-
ing anorectal location and non-epithelial cancers) were
accrued from the personal archives of the authors and
from case reports with available information published in
the literature. Available data regarding demographics
(age, gender), HIV acquisition, ART use, immunosuppres-
sion (AIDS and/or CD4 count), cancer location, pathol-
ogy (tumor grade, TNM stage), and outcome were
extracted and analyzed.
Results
A total of 15 patients were identified, including five per-
sonal cases and 10 published reports. Patients were an
average age of 42 years (range 25–67) and predominantly
male (M:F 12:3), of which six were known intravenous
drug users and four homosexual. Most (59%) carcinomas
involved the right colon, and less frequently the sigmoid
(25%), transverse (8%) or entire (8%) colon. Tumor dif-
ferentiation ranged from grade 1 (17%), to grade 2 (50%)
and grade 3 (33%) carcinomas. Most (62%) were stage 4
cancers, and less often stage 3 (23%) or 2 (15%) malig-
nancies. Metastases when present were mainly to the liver,
but included the lung, ascites and subcutaneous tissue.
Many (62%) individuals died shortly (within 1–26
months) after their cancer diagnosis. Immunosuppres-
sion (AIDS diagnosis and/or CD4 <200 cells/mm3) noted
in eight (53%) individuals did not appear to correlate
with tumor grade, stage, nor an adverse outcome. Neither
did ART use, which was reported in eight (53%) of these
patients.
Conclusion
Adenocarcinoma of the colon should be added to the
growing list of NADC. These data show that HIV-infected
patients manifesting with colon cancer tend to be younger
than their HIV-negative counterparts, with a male pre-
dominance. HIV-associated immunosuppression and
prior exposure to antiretroviral therapy do not appear to
have a major impact on tumor biology or patient out-
come. Frequent involvement of the right colon suggests
that colorectal cancer screening of the entire colon should
be offered to HIV-infected individuals.
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